EKF Diagnostics Holdings (LSE:EKF) has kept a steady flow of announcements coming since publishing its interim results on 15 September 2026. The diagnostics group reported broadly flat Revenue but improved margins for the first half of the year, reiterated that it expects full-year growth in line with market expectations, and has continued to buy back its own shares through late September.
What the Company Does
EKF is a medical diagnostics Business that operates through two main divisions. Its Point-of-Care unit supplies analysers and consumables for hematology, diabetes and lactate testing, while its Life Sciences arm produces enzymes and reagents, including beta-hydroxybutyrate (β-HB) products, and provides fermentation and contract Manufacturing services. The company has said its fermentation and contract manufacturing operations will trade under the Nexus Bioworks name. The Americas is its largest market by revenue.
Latest Developments
In the six months to 30 June 2026, revenue was £25.0 million compared with £25.2 million a year earlier. Point-of-Care sales slipped 3% to £15.0 million, while Life Sciences grew 8% to £10.0 million, helped by a 14% rise in fermentation revenue and a 25% increase in contract manufacturing. The company said much of the delayed Point-of-Care revenue is expected to fall into the second half, supported by its order book.
Operationally, EKF exited its Elkhart, Indiana site on 30 June 2026, a year earlier than originally planned. Chief executive Gavin Jones said the board remained confident of delivering revenue and adjusted EBITDA growth for 2026.
Financial Picture
Gross Margin improved to 53.0% from 50.2%, lifting Gross Profit to £13.3 million. Adjusted EBITDA edged up 2.4% to £5.9 million, while profit before tax was £3.4 million against £3.6 million previously. Profit for the period rose to £2.5 million and Basic Earnings Per Share were 0.54p, up from 0.43p.
Cash generation was softer, with net cash from operations of £3.3 million and free Cash Flow of £1.1 million, down from £4.9 million and £3.7 million respectively. The group held £16.0 million of cash at the end of June, of which £2.4 million was in Russia and subject to restrictions, and reported no borrowings beyond Lease liabilities of about £1.5 million.
No Dividend was paid or declared. Instead, EKF is returning Capital through buybacks: it repurchased 3.55 million shares for £0.9 million in the half, taking total Buybacks since the programme began to 23.5 million shares and £5.9 million. Its latest notice, dated 28 September 2026, showed 80,000 shares bought at 25p on 25 September, leaving 428,073,112 shares in issue.
Sector and index Context
As a member of the FTSE AIM All Share Index, EKF is part of a cluster of smaller UK-listed healthcare and life sciences companies. The group has refocused in recent years on profitable core products after the decline in pandemic-era testing demand, and its medium-term plan rests on growing contract manufacturing and fermentation, expanding β-HB sales and accelerating hematology growth.
Key Risks
Point-of-Care revenue has proved sensitive to order timing, and any further delays could weigh on second-half delivery. Cash conversion weakened in the period, and part of the cash balance is held in Russia under restrictions. The company also noted that a £3 million undrawn Facility expired in March 2026 and was not renewed.
What to Watch Next
Investors will look for evidence that delayed Point-of-Care orders convert in the second half, and for progress towards the market expectations cited by the company of £54.6 million revenue and £13.6 million adjusted EBITDA for 2026. Longer term, EKF has reiterated a target of more than £80 million of revenue and £20 million of adjusted EBITDA by 2029. The pace of buybacks and the build-out of Nexus Bioworks will also be closely followed.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...